The shareholder of DB Ashbourne Limited (DBA) has sold the company to Ethypharm S.A. for an undisclosed consideration.
DBA currently markets and supplies a range of prescription-only medicines to the UK market, generating significant savings for the National Health Service (NHS) and has an exciting pipeline of products in development which will be supplemented with a wide range of additional products from the Ethypharm pipeline.
Ethypharm S.A. is a France-based company engaged in developing, manufacturing and licensing pharmaceutical products. Through the acquisition of DBA, Ethypharm continues to implement its strategy to develop a direct commercial presence in key territories in Europe to market central nervous system products, with a particular focus on pain and innovative treatments for addictions. DBA provides a pivotal platform to generate revenues in the important UK market and this acquisition, along with the deployment of its own commercial operations in France and Germany, will generate a large turnover.
“I am delighted to welcome the DBA team to the Ethypharm group. The acquisition of DBA is a significant step forward for us. The know-how and expertise of both companies are totally complementary and synergistic and DBA offers a great platform to launch products from our own pipeline,” declared Hugues Lecat, CEO of Ethypharm.
Cavendish, an Oaklins member firm in the UK, advised the seller in this transaction.
© Oaklins. All rights reserved. Oaklins refers to Oaklins International Inc. and/or one of its member firms, each of which is a separate legal entity. Please see www.oaklins.com/legal for further details.